CA3226034A1 - Pudexacianinium for nirf imaging - Google Patents
Pudexacianinium for nirf imaging Download PDFInfo
- Publication number
- CA3226034A1 CA3226034A1 CA3226034A CA3226034A CA3226034A1 CA 3226034 A1 CA3226034 A1 CA 3226034A1 CA 3226034 A CA3226034 A CA 3226034A CA 3226034 A CA3226034 A CA 3226034A CA 3226034 A1 CA3226034 A1 CA 3226034A1
- Authority
- CA
- Canada
- Prior art keywords
- pudexacianinium
- free form
- urine
- pharmaceutical composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226534P | 2021-07-28 | 2021-07-28 | |
| US63/226,534 | 2021-07-28 | ||
| PCT/IB2022/056957 WO2023007404A1 (en) | 2021-07-28 | 2022-07-27 | Pudexacianinium for nirf imaging |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226034A1 true CA3226034A1 (en) | 2023-02-02 |
Family
ID=82898903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226034A Pending CA3226034A1 (en) | 2021-07-28 | 2022-07-27 | Pudexacianinium for nirf imaging |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240342316A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4376896A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527715A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240041952A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117715661A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022321011A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226034A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024001242A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023007404A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024084287A1 (en) * | 2022-10-21 | 2024-04-25 | Astellas Pharma Inc. | Composition for near infrared lymphatic imaging and uses and dosages therefor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9056131B2 (en) | 2010-01-28 | 2015-06-16 | National University Corporation Mie University | Indocyanine compound, synthesis method and purification method thereof, diagnostic composition using the indocyanine compound, and device for measuring biokinetics and device for visualizing circulation using the diagnostic composition |
-
2022
- 2022-07-27 JP JP2023580416A patent/JP2024527715A/ja active Pending
- 2022-07-27 AU AU2022321011A patent/AU2022321011A1/en active Pending
- 2022-07-27 US US18/291,487 patent/US20240342316A1/en active Pending
- 2022-07-27 EP EP22754545.6A patent/EP4376896A1/en active Pending
- 2022-07-27 WO PCT/IB2022/056957 patent/WO2023007404A1/en not_active Ceased
- 2022-07-27 CN CN202280052692.7A patent/CN117715661A/zh active Pending
- 2022-07-27 CA CA3226034A patent/CA3226034A1/en active Pending
- 2022-07-27 KR KR1020247005443A patent/KR20240041952A/ko active Pending
- 2022-07-27 MX MX2024001242A patent/MX2024001242A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240041952A (ko) | 2024-04-01 |
| EP4376896A1 (en) | 2024-06-05 |
| AU2022321011A1 (en) | 2024-01-25 |
| WO2023007404A1 (en) | 2023-02-02 |
| CN117715661A (zh) | 2024-03-15 |
| MX2024001242A (es) | 2024-02-13 |
| JP2024527715A (ja) | 2024-07-26 |
| US20240342316A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Garbern et al. | Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium | |
| Dubois et al. | Lymphangiomas in children: percutaneous sclerotherapy with an alcoholic solution of zein. | |
| Li et al. | Mesencephalic astrocyte‐derived neurotrophic factor affords neuroprotection to early brain injury induced by subarachnoid hemorrhage via activating Akt‐dependent prosurvival pathway and defending blood‐brain barrier integrity | |
| AU2018202986B2 (en) | ANG-(1-7) derivative oligopeptides and methods for using and producing the same | |
| CN110267644B (zh) | 用于治疗腺样囊性癌的苯磺酰胺衍生物的医药组合物 | |
| Murase et al. | Randomized, double‐blind, controlled study to evaluate safety and pharmacokinetics of single ascending doses of ASP5354, an investigational imaging product, in healthy adult volunteers | |
| BR112012017435A2 (pt) | processo para a preparação de composições farmacêuticas para a liberação sustentada de análogos de somatostatina | |
| US20240342316A1 (en) | A pharmaceutical composition for imaging | |
| BR112013014642A2 (pt) | produto farmacêutico, kit, uso, produtos, métodos e usos inovadores | |
| JP5211073B2 (ja) | 子宮内膜症の治療用の薬剤 | |
| RU2615767C2 (ru) | Способ лечения сердечной недостаточности и поражения нервных клеток | |
| TW201121992A (en) | Suppression of cancer metastasis | |
| US20250161527A1 (en) | Pharmaceutical compositions for hemostasis and wound healing in gastrointestinal tract | |
| CN100379455C (zh) | 预防或治疗子宫内膜异位症的药物 | |
| Trim et al. | Horses with colic | |
| WO2003074108A2 (en) | Compositions for generating submucosal fluid cushions | |
| HK40104552A (en) | Pudexacianinium for nirf imaging | |
| Yang et al. | Establishment of a novel rat model of different degrees of portal vein stenosis following 70% partial hepatectomy | |
| CN117257803A (zh) | 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用 | |
| TWI426923B (zh) | 在以多層電腦斷層攝影進行之冠狀動脈攝影方法中依伐布雷定(ivabradine)作為診斷劑之用途 | |
| Graham | 25 Vascular Anomalies of the Head and Neck | |
| JP7391400B2 (ja) | 線溶系亢進薬、及びその用途 | |
| RU2857200C2 (ru) | Лекарственное средство dc009 для лечения острого ишемического инсульта | |
| CN103948617A (zh) | 一种治疗和预防腹部手术后粘连的药物组合物 | |
| CN121534039A (zh) | 一种含巴西苏木素的药物组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250526 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250526 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260619 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260619 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260710 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260710 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260710 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260731 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260731 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260731 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260731 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260731 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260731 |